Merck Sees Slightly More Success With External Rx Than Internal Candidates

Merck has a slightly higher success rate with drug candidates developed through external licensing deals than with internally discovered compounds, Merck Senior Director-Strategic Research Initiatives, External Scientific Affairs Ronald Newbold said